The landscape of therapeutic interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor agonists taking center stage. Initially, drugs like Reta, demonstrating impressive glucose control and https://aoifeigxs124703.thelateblog.com/39331218/glp-3-receptor-agonists-reta-trizepatide-and-beyond